Business Wire

AMCS

12.5.2022 09:32:12 CEST | Business Wire | Press release

Share
AMCS to Acquire Quentic – Partners for a Green Future

AMCS, a leading global supplier of integrated cloud-based software and vehicle technology for the environmental, utilities, waste, recycling, and resource industries, announced today that it has entered into an agreement to acquire Quentic, one of the leading solution providers of Software as a Service for EHSQ and ESG management, for an undisclosed amount. The transaction is subject to regulatory approval and is expected to close in the coming weeks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005027/en/

In connection with AMCS’ acquisition of Quentic, Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) is making a new equity investment in AMCS alongside new equity investments from existing investors Insight Partners, Ireland Strategic Investment Fund (ISIF), and Highland Europe.

AMCS continues strong growth globally
With this acquisition, AMCS will be positioned to broaden its expertise in the environmental services industry globally and continue to expand its customer base. With a combined 4,000 customers supported by over 1,000 employees, AMCS is on a trajectory to achieve run rate revenues greater than €180m by the end of the year.

AMCS extends environmental services offering across a wider industry
AMCS and Quentic are now positioned to provide more advanced digital solutions to a wider industry, which will enrich their customers’ operations and impact the environment for a healthier, cleaner, and more sustainable world.

Leveraging expertise to fuel a net zero carbon future
Combining forces is an important step for both companies as they leverage the expertise from each organization and jointly lead the way for added competence in the market. Managing resources from cradle-to-cradle has become a key responsibility for businesses across all industries. The integration of AMCS and Quentic enables customers on both sides to benefit from a wide range of solutions that support end-to-end standardization and optimization of business processes to increase efficiencies, streamline operations and work toward a safe and sustainable future.

“AMCS and Quentic are very aligned with the mission to drive an environmentally sustainable future”, says Jimmy Martin, CEO of AMCS. “A net zero carbon future depends on a very connected and circular approach across the supply chain. We are thrilled to bring the technology from Quentic into the AMCS portfolio of solutions and can now move forward with a focus on influencing the entire supply chain, offering smarter outcomes from automating and digitizing their businesses -- reducing waste as much as possible.”

Quentic adds 15 years of EHSQ excellence to AMCS’ portfolio
CEO Markus Becker, COO Sebastian Mönnich and CTO Hardy Menzel founded Quentic, formerly EcoIntense, in 2007 to provide software for environmental management. Today, Quentic provides a holistic and modular Software as a Service solution to manage all tasks and processes related to environmental, health, safety, and quality management (EHSQ) as well as corporate responsibility-related areas in environment, social and governance (ESG).

“We have built Quentic on the values of making a meaningful contribution to people, society and the environment”, Markus Becker, CEO of Quentic said. “Therefore, we are excited to have found a partner in AMCS who fully aligns with our mission to digitally empower companies across the globe to manage people, business and environmental processes sustainably at all levels. Together with AMCS, the Quentic management team will continue to shape the future.”

About AMCS

AMCS is headquartered in Limerick, Ireland with offices in North America, Europe, and Australia employing over 800 people across 12 countries. AMCS is a global leader of integrated software and vehicle technology for the environmental, recycling, and resource industries and offers optimization solutions to the broader transport and logistics market. AMCS helps over 3,000 customers in 22 countries to reduce their operating costs, increase asset utilization, optimize margins, and improve customer service. Their enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world.

About Quentic

Quentic is one of the leading solution providers of Software as a Service (SaaS) for EHSQ and ESG management. The Quentic platform comprises ten individually combinable modules and offers an ideal way for companies to manage Health & Safety, Risks & Audits, Incidents & Observations, Hazardous Chemicals, Control of Work, Legal Compliance, Online Instructions, Processes, Environmental Management and Sustainability.

The company is headquartered in Berlin, Germany, and employs more than 250 people. Branch offices are located in Germany, Austria, Switzerland, Finland, Sweden, Denmark, Belgium, the Netherlands, France, Spain and Italy.

About Clearlake Capital Group, L.P.

Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with management teams by providing patient, long-term capital to businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has over $72 billion of assets under management, and its senior investment principals have led or co-led over 400 investments. The firm is headquartered in Santa Monica, CA with affiliates in Dallas, TX, London, UK and Dublin, Ireland. More information is available at www.clearlake.com and on Twitter @Clearlake.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye